TIDMEKF
RNS Number : 1907T
EKF Diagnostics Holdings PLC
23 November 2021
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Directorate Change
Appointment of Chief Financial Officer
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed
point-of-care business , announces the appointment of Marc Davies
as Chief Financial Officer ("CFO"). Marc will join the Board as CFO
on 1 January 2022, and will succeed Richard Evans, currently Chief
Operating Officer and Finance Director, who will step down from his
position on 1 January 2022 but remain with the Company until the
end of March 2022 to provide a suitable handover period.
Marc joins EKF from medical device designer, manufacturer and
supplier Flexicare Medical, where he is currently Group Finance and
Operations Director. Marc has been responsible for overseeing
substantial revenue growth throughout his time with the business,
driven by both organic performance and acquisition. Since joining
Flexicare Medical as Finance Director in 2017, Marc has led several
corporate finance transactions including post-transaction
integration.
Previously, Marc was a Corporate Finance Director at PwC,
providing mid-market private business and private equity focused
corporate finance advice as Head of the PwC West and Wales
Corporate Finance Team. Before joining PwC in February 2013 Marc
was an AIM focussed Corporate Finance Advisor for over five years,
during which he spent four years at WH Ireland, including work
within its Nominated Adviser function. Marc began his career in
finance as part of the PwC Corporate Recovery team.
Marc is a Fellow Chartered Accountant (FCA) and an Oxford
graduate with an MSc (Distinction) in Mathematical Modelling and
Scientific Computation and an MA (First Class) in Mathematical
Science.
Christopher Mills, Chairman of EKF, commented:
"I would like to take this opportunity to again thank Richard
for more than ten years of service to the Company, and for his
efforts in ensuring continuity by remaining with us until the end
of March.
"We are delighted to have Marc join EKF in the new year to
support Mike Salter and the EKF team as we implement the next
phases of our growth strategy looking out to 2024. Not only does
Marc have strong sector experience managing both organic and
acquisitive growth, but also a solid advisory background with a
strong understanding of dynamic growth companies such as EKF."
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0)29 2071 0570
Mike Salter, CEO
Richard Evans, FD & COO
Singer Capital Markets (Nominated Adviser & Tel: +44 ( 0)20 7496 3000
Joint Broker)
Aubrey Powell / George Tzimas / Tom
Salvesen
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584 391
303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analysers in regular use
across more than 100 countries. EKF specialises in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analysers.
EKF specialises in the development, production and worldwide
distribution of point-of-care analyzers and clinical chemistry
reagents for use in hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia screening programmes.
EKF is also a bulk manufacturer of enzymes and has custom
manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. Driven by customer demand EKF
has invested significantly in increasing the Company's fermentation
capacity. The Company's capabilities and capacity in contract
manufacturing for sample collection, tests and test kits have seen
dramatic growth following strong demand for during the COVID-19
pandemic, and these income streams are now being diversified for
application to other non-COVID areas of diagnostic testing,
molecular disease and forensic test manufacture.
In May 2021, EKF outlined its strategy through to 2024 for
delivering additional growth. As well as the growth expected in
Contract Manufacturing across Life Sciences, molecular diagnostics
and other applications, the Company expects to leverage existing
distribution channels for organic growth, both in the core business
and from additional products to expand the core range, but also
through executing earnings enhancing acquisitions and delivering
further value creating investments associated with the preferred
partnership agreement with Mount Sinai Innovation Partners.
In October 2021, EKF completed the acquisition of Advanced
Diagnostic Laboratory LLC, a Texas based testing laboratory
certified under the Clinical Laboratory Improvement Amendments
("CLIA") for high complexity testing. The laboratory provides
testing for a variety of clinical, forensic and microbiological
sample types using a range of analytical techniques. This
acquisition positions EKF as a leading 'one stop' provider of
diagnostic products and services from sample collection to
results.
Additional Disclosures Required under the AIM Rules for
Companies
Marc Peter Davies (aged 41) has held the following directorship
or partnerships in the past five years:
Current directorships and partnerships:
Flexicare (Group) Limited
Flexicare Medical Limited
Flexicare GmbH
Flexicare BV
Flexicare Srl
Flexicare Deutschland GmbH
Flexicare Ventures Limited
Flexicare Medical Mexico S.A. DE C.V.
Previous directorships and partnerships held in the past five
years:
None other than former subsidiaries of Flexicare (Group) Limited
with no trading activities.
Marc Davies does not hold any ordinary shares in the
Company.
Save as disclosed above, there is no further information to be
disclosed in respect of the above appointments pursuant to Rule 17
and Schedule 2 paragraph (g) of the AIM Rules for Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPGRAGUPGGRP
(END) Dow Jones Newswires
November 23, 2021 02:00 ET (07:00 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De May 2023 a Jun 2023
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Jun 2022 a Jun 2023
